LON:CIR - Circassia Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started GBX 83.10 -0.85 (-1.01 %) (As of 07/16/2018 06:30 AM ET)Previous CloseGBX 83.95Today's RangeGBX 82.77 - GBX 85.3352-Week RangeN/AVolume19,955 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileAnalyst RatingsInsider TradesHeadlinesChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide. It is also developing various novel specialty treatments for COPD, including Spiriva substitute, Novel LABA/LAMA formulation, and novel COPD therapy formulation. In addition, the company' development pipeline includes a range of treatments for allergies, such as cat allergy, grass allergy, house dust mite allergy, and ragweed allergy. It has a collaboration agreement with AstraZeneca to promote Tudorza for COPD treatment, and has the US commercial rights to late-stage COPD product Duaklir. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom. Receive CIR News and Ratings via Email Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolLON:CIR CUSIPN/A Webwww.circassia.co.uk PhoneN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap£0.00 Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions What is Circassia Pharmaceuticals' stock symbol? Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR." What price target have analysts set for CIR? 3 analysts have issued 1-year target prices for Circassia Pharmaceuticals' shares. Their forecasts range from GBX 100 to GBX 140. On average, they anticipate Circassia Pharmaceuticals' stock price to reach GBX 120 in the next twelve months. This suggests a possible upside of 44.4% from the stock's current price. View Analyst Ratings for Circassia Pharmaceuticals. What is the consensus analysts' recommendation for Circassia Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Circassia Pharmaceuticals' key competitors? Some companies that are related to Circassia Pharmaceuticals include Altimmune (ALT), Can-Fite Biopharma (CANF), Cronos Group (CRON), Devonian Health Group (GSD), Exicure (XCUR), Galena Biopharma (SLS), Immunoprecise Antibodies (IPATF), IMV (IMV), Naturally Splendid Enterprises (NSP), Novacyt (NCYT), Nuformix (NFX), Sirona Biochem (SBM) and Synthetic Biologics (SYN). Who are Circassia Pharmaceuticals' key executives? Circassia Pharmaceuticals' management team includes the folowing people: Mr. Steven Charles Andrew Harris, Co-Founder, Chief Exec. Officer and Director (Age 51)Mr. Julien Cotta, Chief Financial Officer, Company Sec. and Director (Age 54)Dr. Roderick Peter Hafner, Sr. VP R&D and Director (Age 52)Mr. Matthew Frankel, Gen. CounselMs. Nina Kataria, Sr. VP Global HR Has Circassia Pharmaceuticals been receiving favorable news coverage? News stories about CIR stock have been trending positive on Monday, according to Accern. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Circassia Pharmaceuticals earned a daily sentiment score of 0.43 on Accern's scale. They also assigned news stories about the company an impact score of 45.66 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of Circassia Pharmaceuticals? Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Circassia Pharmaceuticals' stock price today? One share of CIR stock can currently be purchased for approximately GBX 83.10. MarketBeat Community Rating for Circassia Pharmaceuticals (LON CIR)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 2 (Vote Outperform)Underperform Votes: 1 (Vote Underperform)Total Votes: 3MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CIR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?